May 21 (Reuters) - Eli Lilly and Co LLY.N:

• ELI LILLY: RETATRUTIDE 12 MG ACHIEVED 30.3% AVERAGE WEIGHT LOSS AT 104 WEEKS IN EXTENSION

• ELI LILLY: 45.3% OF RETATRUTIDE 12 MG PATIENTS ACHIEVED ≥30% WEIGHT LOSS AT 80 WEEKS

• ELI LILLY: RETATRUTIDE 9 MG ACHIEVED 25.9% AVERAGE WEIGHT LOSS AT 80 WEEKS

• ELI LILLY: RETATRUTIDE DELIVERED POWERFUL WEIGHT LOSS IN PIVOTAL PHASE 3 OBESITY TRIAL

• ELI LILLY: 65.3% OF RETATRUTIDE 12 MG PATIENTS ACHIEVED BMI <30 AT 80 WEEKS

• ELI LILLY: RETATRUTIDE 4 MG ACHIEVED 19.0% AVERAGE WEIGHT LOSS AT 80 WEEKS WITH SINGLE ESCALATION

• ELI LILLY: RETATRUTIDE 4 MG HAD 4.1% DISCONTINUATION RATE DUE TO ADVERSE EVENTS VERSUS 4.9% PLACEBO

• ELI LILLY: RETATRUTIDE 12 MG ACHIEVED 28.3% AVERAGE WEIGHT LOSS AT 80 WEEKS IN TRIUMPH-1

Source text: [ID:]

Further company coverage: LLY.N